Literature DB >> 18036641

Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer.

James Greenaway1, Roger Moorehead, Patricia Shaw, Jim Petrik.   

Abstract

OBJECTIVE: Ovarian cancer is the fourth leading cause of cancer-related deaths among women and is among the least understood of all cancers. The objective of this study was to determine the effect of ovarian epithelial and stromal cell interaction in a mouse model of epithelial ovarian cancer (EOC) that closely resembled the human disease.
METHODS: A mouse model of EOC was generated by orthotopic injection of an ID8 mouse ovarian surface epithelial cell line (MOSEC) under the ovarian bursa of syngeneic mice and tissue was collected to evaluate factors contributing to the formation and development of ovarian tumors.
RESULTS: By 90 days post-injection, mice were moribund and had developed large primary ovarian tumors, secondary tumors within the peritoneal cavity, and extensive ascites fluid production. Tumors were hypervascularized and were characterized as serous epithelial carcinomatosis, which replicates the most common form of human ovarian cancer. Cells isolated from ascites fluid were more proliferative with increased expression of survival factors compared to original MOSEC cells and cells obtained from the abdomen following intraperitoneal injection. Orthotopic injection of these cells under the ovarian bursa resulted in more aggressive tumorigenesis, with mice becoming moribund at 60 days post-injection compared with 90 days post-injection with the original ID8-MOSEC cell line. DISCUSSION: This study describes the generation of an orthotopic, syngeneic model of ovarian cancer, which replicates the phenotype of the human disease. Expression of angiogenic and proliferative factors, and the interaction of epithelial cells with the ovarian stroma are important factors in ovarian tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18036641     DOI: 10.1016/j.ygyno.2007.10.035

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  48 in total

1.  Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.

Authors:  Samantha Russell; Mark Duquette; Joyce Liu; Ronny Drapkin; Jack Lawler; Jim Petrik
Journal:  FASEB J       Date:  2014-11-13       Impact factor: 5.191

Review 2.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

3.  Enhanced anti-tumor efficacy and safety with metronomic intraperitoneal chemotherapy for metastatic ovarian cancer using biodegradable nanotextile implants.

Authors:  Smrithi Padmakumar; Neha N Parayath; Shantikumar V Nair; Deepthy Menon; Mansoor M Amiji
Journal:  J Control Release       Date:  2019-05-17       Impact factor: 9.776

4.  The role of dysregulated glucose metabolism in epithelial ovarian cancer.

Authors:  L D Kellenberger; J E Bruin; J Greenaway; N E Campbell; R A Moorehead; A C Holloway; J Petrik
Journal:  J Oncol       Date:  2010-02-17       Impact factor: 4.375

5.  Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model.

Authors:  Jyothi Thyagabhavan Mony; Lixin Zhang; Tianzhou Ma; Shannon Grabosch; Tejas S Tirodkar; Joan Brozick; George Tseng; Esther Elishaev; Robert P Edwards; Xin Huang; Anda M Vlad
Journal:  Cancer Immunol Immunother       Date:  2015-05-22       Impact factor: 6.968

6.  Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.

Authors:  Kristy K Ward; Isabelle Tancioni; Christine Lawson; Nichol L G Miller; Christine Jean; Xiao Lei Chen; Sean Uryu; Josephine Kim; David Tarin; Dwayne G Stupack; Steven C Plaxe; David D Schlaepfer
Journal:  Clin Exp Metastasis       Date:  2012-12-30       Impact factor: 5.150

7.  Comparative biodistribution of PAMAM dendrimers and HPMA copolymers in ovarian-tumor-bearing mice.

Authors:  S Sadekar; A Ray; M Janàt-Amsbury; C M Peterson; H Ghandehari
Journal:  Biomacromolecules       Date:  2010-12-03       Impact factor: 6.988

8.  Development of a syngeneic mouse model of epithelial ovarian cancer.

Authors:  Bridget A Quinn; Fang Xiao; Laura Bickel; Lainie Martin; Xiang Hua; Andres Klein-Szanto; Denise C Connolly
Journal:  J Ovarian Res       Date:  2010-10-19       Impact factor: 4.234

9.  Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination.

Authors:  Natalie M Moss; Maria V Barbolina; Yueying Liu; Limin Sun; Hidayatullah G Munshi; M Sharon Stack
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

10.  Ovarian cancer mouse models: a summary of current models and their limitations.

Authors:  Miranda Y Fong; Sham S Kakar
Journal:  J Ovarian Res       Date:  2009-09-28       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.